ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 700

Sleep Quality Among Patients with Systemic Lupus Erythematosus

Alexandra Schwab1 and Diane Kamen 2, 1Medical University of South Carolina, Charleston, SC, 2Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: sleep disorders and fatigue, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: SLE – Clinical Poster I: Epidemiology & Pathogenesis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Poor sleep quality is a frequent concern among patients with systemic lupus erythematosus (SLE) and contributes to fatigue and other comorbidities. This study investigates the prevalence of poor sleep quality among patients with SLE and the relationship between sleep quality and SLE-related medication use.

Methods: Patients with SLE participating in a longitudinal observational study at a single academic center were invited by email to complete a web-based sleep questionnaire and medication inventory. The Pittsburg Sleep Quality Index (PSQI), a self-reported validated questionnaire ascertaining sleep habits over the past month, was the metric chosen for measuring sleep quality and was scored using the PSQI scoring algorithm. Demographics, medical history including classification criteria for SLE and SLE disease damage scores were obtained from the existing research registry for each participant.  Pearson’s chi-squared testing was performed for categorical measures and two-sample t-tests were performed for continuous measures. Significance was set at alpha = 0.05.

Results: Of the 142 patients that completed the Pittsburg Sleep Quality Index (PSQI), 99% were female and 86% were African American. The mean PSQI score was 11.98 +/- sd 3.63 with a minimum score of 4 and maximum of 20 out of a possible 21. Higher PSQI scores (corresponding to worse sleep quality) were significantly associated with getting less than 7 hours of sleep (p< 0.01), taking sleep medications at least weekly (p< 0.01), and having a diagnosis of obstructive sleep apnea (p< 0.01), but there was no significant difference found between patients based on age, race, history of lupus nephritis or accumulated disease damage by SLICC-DI.  Having a poor PSQI score was not associated with prednisone dose (p= 0.09), however taking greater than 7mg of prednisone daily was inversely correlated to the number of hours patients slept per night (p< 0.01).  Mean number of hours per sleep per night was 5.7 +/- sd 1.5, despite a mean of 8.0 +/- sd 2.0 hours spent in bed.  42.3% of patients reported taking medications for sleep at least once a week.

Conclusion: In this study of patients with SLE, we found a high prevalence of poor quality sleep and a mean of less than 6 hours of sleep/24 hours despite an average of 2 additional hours spent in bed. Although we did not find SLE-specific predictors of poor sleep quality, the overall sleep habits of the patients reflect a critical need to address sleep with patients and work toward interventions for improvement of sleep quality.


Disclosure: A. Schwab, None; D. Kamen, None.

To cite this abstract in AMA style:

Schwab A, Kamen D. Sleep Quality Among Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/sleep-quality-among-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sleep-quality-among-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology